References

aids

ВИЧ-инфекция и иммуносупрессии

HIV Infection and Immunosuppressive Disorders

2077-9828

Baltic Medical Education Center

10.22328/2077-9828-2016-8-1-7-18

aids-134

Research Article

АНАЛИТИЧЕСКИЙ ОБЗОР

ANALYTICAL REVIEW

МУЖСКОЙ ГИПОГОНАДИЗМ НА ФОНЕ ВИЧ-ИНФЕКЦИИ

HIV-ASSOCIATED MALE HYPOGONADISM

Сурженко

Дария Михайловна

Surzhenko

D. M.

makinad@mail.ru

Кузик

Валерий Владимирович

Kuzik

V. V.

kuzikvv@mail.ru

Санкт-Петербургский центр по профилактике и борьбе со СПИД и инфекционными заболеваниями; Институт эволюционной физиологии и биохимии им. И.М.Сеченова РАНРоссияSaint-Petersburg Center for Control of AIDS and Infectious Diseases; I.M.Sechenov Institute of Evolutionary Physiology and BiochemistryRussian Federation

Институт эволюционной физиологии и биохимии им. И.М.Сеченова РАНРоссияI.M.Sechenov Institute of Evolutionary Physiology and BiochemistryRussian Federation

2016

30032016

81718

2016

Сурженко Д.М., Кузик В.В.

Surzhenko D.M., Kuzik V.V.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://hiv.bmoc-spb.ru/jour/article/view/134

Гипогонадизм встречается у 15-25% ВИЧ-инфицированных мужчин. По происхождению гипогонадизм чаще является гипогонадотропным, реже имеет тестикулярную этиологию. Помимо нарушения половой функции, для больных гипогонадизмом характерны: депрессия, анемия, снижение мышечной и костной массы. При отсутствии противопоказаний лечение проводится препаратами тестостерона или гонадотропинами. Осложнения при терапии препаратами тестостерона проявляются в виде гиперплазии простаты, увеличения риска развития рака предстательной железы, полицитемии и апноэ во сне, причем риск этих осложнений увеличивается с возрастом пациентов. Скрининг на гипогонадизм проводится среди пациентов при наличии эректильной дисфункции и депрессивных состояний и заключается в определении уровня тестостерона и глобулина, связывающего половые стероиды.

Hypogonadism is found in 15-25% of male HIV patients. This condition is most often hypogonadotrophic by its origin. Less often, its etiology is testicular. Besides impaired sexual functions, such patients experience depression, anemia, and decreased muscular and skeletal mass. When there are no contraindications, testosterone and gonadotropin preparations are used for therapy. The complications of testosterone therapy are manifested as prostate hyperplasia, increased risk of prostate cancer, polycythemia, and sleep apnea. Their risk increase with patients’ age. Screening for hypogonadism is indicated for patients having erectile dysfunctions and depression and includes tests for testosterone and sex steroid-binding globulin.

ВИЧ-инфекциядефицит тестостеронагипогонадизмHIV infectiontestosterone deficithypogonaism

References1

Хоффман К., Рокштро Ю.К. ВИЧ 2014/2015.- 942 с.

d’Anglemont de T.X., Fagg L.A., Dixon J.P., Day K., Leitch H.G., Hendrick A.G., Zahn D., Franceschini I., Caraty A., Carlton M.B., Aparicio S.A., Colledge W.H. Hypogonadotropic hypogonadism in mice lacking a functional Kiss 1 gene // Proc. Natl. Acad. Sci. USA.- 2007.- № 104.- P. 10 714-10 719.

Allan C.A. Sex steroids and glucose metabolism // Asian J. Andrology.-2014.- № 16.- P 232-238.

American Association of Clinical Endocrinologists medical guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients-2002 update // Endocr. Pract.- 2002.- № 8.- P 440-456.

Amini-Lari M., Parse N., Marzban M., Shams M., Faramarzi H. Depression, testosterone concentration, sexual dysfunction and methadone use among men with hypogonadism and HIV infection // AIDS Behav.- 2012.- Vol. 16, № 8.- P. 2236-2243.

Ashby J., Goldmeier D., Sadeghi-Nejad H. Hypogonadism in human immunodeficiency virus-positive men // J. Urol.- 2014.- Vol. 55.- P 9-16.

Bhasin S., Storer T.W., Asbel-Sethi N. Effects of testosterone replacement with a nongenital, transdermal system, Androderm, in human immunodeficiency virus-infected men with low testosterone levels // J. Clinical Endocrinol. Metabolism.- 1998.- Vol. 83, № 9.- P 3155-3162.

Calza L., Masetti G., Piergentili B., Trapani F., Cascavilla A., Manfredi R. Prevalence of diabetes mellitus, hyperinsulinaemia and metabolic syndrome among 755 adult patients with HIV-1 infection // Int. J. STD AIDS.- 2011.- № 22.- P 43-45.

Castellano J.M., Navarro V.M., Fernandez-Fernandez R. et al. Changes in hypothalamic KiSS-1 system and restoration of pubertal activation of the reproductive axis by kisspeptin in undernutrition // Endocrinology.- 2005.- № 146.- P 3917-3925.

Cohan G.R. HIV-associated hypogonadism // AIDS Read.- 2006.- № 16.- P 341-345.

Corona G., Rastrelli G., Forti G., Maggi M. Update in testosterone therapy for men // J. Sex. Med.- 2011.- № 8.- P 639-654.

Corona G., Rastrelli G., Vignozzi L., Mannucci E., Magi M. Testosterone cardiovascular disease and the metabolic syndrome // Best. Pract. Res. Clin. Endocrinol. Metab.- 2011.- № 25.- P 337-353.

Corona G., Rastrelli G., Morelli A., Vignozzi L., Mannucci E. Hypogonadism and metabolic syndrome // J. Endocrinol. Invest.- 2011.- № 34.- P 557-567.

Corona G., Rastrelli G., Vignozzi L., Maggi M. Emerging medication for the treatment of male hypogonadism // Expert Opin. Emerg. Drugs.- 2012.- № 17.- P 239-259.

Corona G., Vignozzi L., Sforza A., Maggi M. Risks and benefits of the late onset hypogonadism treatment: and expert opinion // World J. Mens health.- 2013.- Vol. 31, № 2.- P. 103-125.

Cooper O.B., Brown T.T., Dobs A.S. Opiate drug use: a potential contribution to the endocrine and metabolic complications in human immunodeficiency virus disease // Clin. Infect. Dis.- 2003.- Vol. 37 (suppl. 2).- P. 132-136.

Cotter A.G., Powderly W.G. Endocrine complications of human immunodeficiency virus infection: hypogonadism, bone disease and tenofovir-rela-ted toxicity // Best Pract. Res. Clin. Endocrinol. Metab.- 2011.- Vol. 25, № 33.- Р. 501-515.

Crum-Cianflone N.F., Bavaro M., Hale B., Amiling C., Truett A., Brandt C. Erectile disfunction and hypogonadism among men with HIV // AIDS Patient Care STDS.- 2007.- № 21.- Р. 9-19.

Cubero J.M., Domingo P., Sambeat M., Ordonez-Llanos J., Rodriguez-Espinosa J., Snchez-Quesada J.L. Prevalence of metabolic syndrome among human immunodeficiency virus-infected subjects is widely influenced by the diagnostic criteria // Metab. Syndr. Relat. Disord. - 2011. - № 9.- Р. 345-351.

Darby E., Anawalt B.D. Male hypogonadism: an update on diagnosis and treatment // Treat. Endocrinol.-2005.- Vol. 4, № 5.- Р. 293-309.

De Paepe M.E., Vulentin J.C., Lee M.H. Testicular atrophy in homosexual AIDS patints: an immune-mediated phenomenon? // Human Pathology.- 1989.- Vol. 20, № 6.- Р. 572-578.

Desyatnik M., Baaj A., Fisher A. The prevalence of hypogonadism in HIV-infected patients receiving HAART (TuPeB3180) // Poster session presented at: 13th International AIDS Conference; 2000 Jul 9-14; Durban, South Africa.

Dobs A.S., Dempsey M.A., Ladenson P.W., Polk B.F Endocrine disorders in men infected with human immunodeficiency virus // Am. J. Med. - 1988.- № 84.- Р. 611-616.

Dobs A.S., Cofranceso J., Nolten W.E. The use of a transscrotal testosterone delivery system in the treatment of patients with weight loss related to human immunodeficiency virus infection // American Journal of Medicine.- 1999.- Vol. 107, № 2.- Р. 126-132.

Dube M.P., Parker R.A., Mulligan K., Tebas P., Robbins G.K., Roubenoff R. Effects of protein antiretroviral therapy on free testosterone levels and fat-free mass in men in a prospective, randomized trial: A5005s, a substudy of AIDS Clinical Trials Group Study 384 // Clin. Infect. Dis.- 2007.- № 45.- Р.120-126.

Dungan H.M., Clifton D.K., Steiner R.A. Minireview: kisspeptin neurons as central processors in the regulation of gonadotropin-releasing hormone secretion // Endocrinology.- 2006.- № 147.- Р. 1154-1158.

Grinspoon S., Corcoran C., Askari H. Effects of androgen administration in men with the AIDS wasting syndrome: a randomized, double-lind, placebo-controlled trail // Ann. Intern. Med.- 1998.- № 129.- Р. 18-26.

Grinspoon S., Concoran A., Anderson E. Sustained anabolic effects of long-term androgen administration in men with AIDS wasting // Clinical Infectious Diseases.- 1999.- Vol. 28, № 3.- Р. 634-636.

Grinspoon S., Corcoran C., Stanley T., Baaj A., Basgoz N., Klibanski A. Effects of hypogonadism and testosterone administration on depression indices in HIV-infected men // J. Clin. Endocrinol. Metab.- 2000.- № 85.- Р. 60-65.

Grinspoon S. Androgen deficiency and HIV infection // HIV/AIDS.- 2005.- № 41.- Р. 1804-1805.

Guaraldi G., Beggi M., Zona S., Luzi K., Orlando G. Erectile dysfunction is not a mirrow of endothelial dysfunction in HIV-infected patients // J. Sex. Med.- 2012.- Vol. 9, № 4.- Р. 1114-1121.

Fairfield W.P., Treat M., Rosenthal D.I. Effects of testosterone and exercise on muscle leanness in eugonadal men with AIDS wasting // J. Appl. Physiol.- 2001.- № 90.- Р. 2166-2171.

Forbes S., Li X.F., Kinsey-Jones J., O’Byrne K. Effects of ghrelin on Kisspeptin mRNA expression in the hypothalamic medial preoptic area and pulsatile luteinising hormone secretion in the female rat // Neurosci. Lett.- 2009.- № 460.- Р. 143-147.

Kelly D.M., Jones T.H. Testosterone: a metabolic hormone in health and disease // J. Endocrinol.- 2013.- № 217.- Р. 25-45.

Klein R., Lo Y., Santoro N., Dobs A. Androgen levels in older men who have or who are at risk of acquiring HIV infection // Clin. Infect. Dis.- 2005.- № 41.- P 1794-1803.

Lallemand F., Salhi Y., Linard F., Giami A., Rozenbaum W. Sexual dysfunction in 156 ambulatory HIV-infected men receiving highly active antiretroviral therapy combinations with and without protease inhibitors // J. Acquir. Immune Defic. Syndr.- 2002.- № 30.- Р. 187-190.

Laudat A., Blum L., Guechot J., Picard O., Cabane J., Imbert J.C., Giboudeau J. Changes in systemic gonadal and adrenal steroids in asymptomatic human immunodeficiency virus-infected men: relationship with the CD4 cells counts // Eur. J. Endocrinol.- 1995.- Vol. 133, № 4.- Р. 418-424.

McLachlan R.I., Allan C.A. Defining the prevalence and incidence of androgen deficiency in aging men: where are the goal post? // J. Clin. Endocrinol. Metab.- 2004.- № 89.- Р. 5916-5919.

Moreno-Pereze O., Escoin C., Serna-Candel C., Portilla J., Boix V., Alfayate R. The determination of total testosterone and free testosterone (RIA) are not applicable to the evaluation of gonadal function in HIV-infected males // J. Sex. Med.- 2010.- № 7.- Р. 2873-2883.

Morley J.E., Charlton E., Patrick P. Validation of a screening questionnaire for androgen deficiency in aging males // Metabolism.- 2000.- № 99.- Р. 1239-1242.

Rabkin J.G., Wagner G.J., Rabkin R. A double-bind, placebo-controlled trail of testosterone therapy for HIV-positive men with hypogonadal symptoms // Archives of General Psychiatry.- 2000.- Vol. 57, № 2.- Р. 141-147.

Rietschel P., Corcoran C., Stanley T. Prelevance of hypogonadism among men with weight loss related to human immunodeficiency virus infection who were receiving highly active antiretroviral therapy // Clinical Infectious Diseases.- 2000.- Vol. 31, № 5.- Р. 1240-1244.

Rivkees S.A., Crawford J.D. The relationship of gonadal activity and chemotherapy-induced gonadal damage // JAMA. -1988.- Vol. 259, № 14.- Р. 2123-2125.

Richardson D., Goldmeier D., Frize G., Lamba H., De Souza C., Kocsis A. Letrozole versus testosterone. A single-center pilot study of HIV-infected men who have sex with men on highly active anti-retroviral therapy (HAART) with hypoactive sexual desire disorder and raised estradiol levels // J. Sex. Med.- 2007.- № 4.- Р. 502-508.

Rodriguez A., Muller D.C., Metter E.J., Maggio M., Harman S.M., Blackman M.R. Aging, androgens and the metabolic syndrome in a longitudinal study of aging // J. Clin. Endocrinol. Metab.- 2007.- № 92.- Р. 3568-3572.

Roubenoff R., Grinspoon S., Skolnik P.R., Tchetgen E., Abad L., Spiegelman D. Role of cytokines and testosterone in regulating lean body mass and resting energy expenditure in HIV-infected men // Am. J. Physiol. Endocrinol. Metab.- 2002.- № 283.- Р. 138-145.

de Roux N., Genin E., Carel J.C., Matsuda F., Chaussain J.L., Milgrom E. Hypogonadotropic hypogonadism due to loss of function of the KiSS1-derived peptide receptor GPR54 // Proc. Natl. Acad. Sci. USA.- 2003.- № 100.- Р. 10972-10976.

Scott J.D., Wolfe P.R., Anderson P. Prospective study of topical testosterone gel (AndroGel) versus intramuscular testosterone in testosterone-deficient HIV-infected men // HIV Clinical Trails.- 2007.- Vol. 8, № 6.- Р. 412-420.

Sellmeyer D.E., Grunfeld C. Endocrine and metabolic disturbances in human immunodeficiency virus infection and the acquired immune deficiency syndrome // Endocr. Rev.- 1996.- Vol. 17, № 5.- Р. 518-532.

Siddiqui J., Phillips A.L., Freeland E.S., Sklar A.R., Darkow T., Harley C.R. Prevalence and cost of HIV-associated weight loss in a managed care population // Curr. Med. Res. Opin.- 2009.- № 25.- Р. 1307-1317.

Topaloglu A.K., Tello J.A., Kotan L.D. Inactivating KISS1 mutation and hypogonadotropic hypogonadism // N. Engl. J. Med.- 2012.- № 366.- Р. 629-635.

Vermeulen A., Verdonck L., Kaufman J.M. A critical evaluation of simple methods for the estimation of free testosterone in serum // J. Clin. Endocrinol. Metab. -1999.- № 84.- Р. 3666-3672.

Ullah M.I., Riche D.M., Koch C.A. Transdermal testosterone replacement therapy in men.- 2014.- № 8.- Р. 101-112.

Wunder D.M., Bersinger N.A., Fux C.A., Mueller N.J. Hypogonadism in HIV-1-infected men is common and does not resolve during antiretroviral therapy // Antivir. Ther.- 2007.- № 12.- Р. 261-265.

Zona S., Guaraldi G., Luzi K., Beggi M., Santi D., Stentarelli C., Madeo B., Rochira V. Erectile dysfunction is more common in young to middle-aged HIV-infected men than in HIV-uninfected men // J. Sex. Med.- 2012.- № 7.- Р. 1923-1930.

revised classification system for HIV infection and expanded surveillance case definition for AIDE among adolescents and adults // MMWR Recomm. Rep. -1992.- № 41.- Р. 1-19.

The authors declare that there are no conflicts of interest present.